Published in Proc Natl Acad Sci U S A on June 22, 1999
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ (2002) 7.26
The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol (2013) 5.57
COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A (2002) 4.80
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
The double-edged sword of COX-2 selective NSAIDs. CMAJ (2002) 2.57
Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2). Mol Cell Biol (2004) 2.25
Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation (2014) 2.11
Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria. Blood (2010) 1.73
Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol (1999) 1.65
Key questions concerning paracetamol and NSAIDs for osteoarthritis. Ann Rheum Dis (2002) 1.64
Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids (2009) 1.54
Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci U S A (2002) 1.48
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest (2001) 1.45
Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci U S A (2002) 1.44
Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis (1999) 1.42
Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam. J Thorac Dis (2014) 1.40
Pharmacological characterisation of a rat model of incisional pain. Br J Pharmacol (2003) 1.35
Nociception in cyclooxygenase isozyme-deficient mice. Proc Natl Acad Sci U S A (2000) 1.32
Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis. ScientificWorldJournal (2012) 1.29
Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol (2007) 1.25
Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology (2009) 1.19
Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther (2006) 1.16
Layer-by-layer platform technology for small-molecule delivery. Angew Chem Int Ed Engl (2009) 1.15
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem J (2001) 1.14
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A (2001) 1.13
Drug repurposing: far beyond new targets for old drugs. AAPS J (2012) 1.09
Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol (2002) 1.06
Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. PLoS One (2011) 1.06
Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer (2004) 1.03
Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol (2001) 1.03
Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol (2000) 1.02
A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives. PLoS One (2007) 1.01
Diosgenin, a plant steroid, induces apoptosis in human rheumatoid arthritis synoviocytes with cyclooxygenase-2 overexpression. Arthritis Res Ther (2004) 1.01
Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res (Phila) (2010) 1.00
Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol (2005) 0.99
A comparison of the effects of ibuprofen and rofecoxib on rabbit fibula osteotomy healing. Acta Orthop (2009) 0.99
Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol (2002) 0.98
Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2. J Exp Clin Cancer Res (2008) 0.97
Flavonoid fraction of Bergamot juice reduces LPS-induced inflammatory response through SIRT1-mediated NF-κB inhibition in THP-1 monocytes. PLoS One (2014) 0.95
Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut (2005) 0.95
Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime? Br J Clin Pharmacol (2006) 0.95
Acetaminophen-induced hypothermia in mice is mediated by a prostaglandin endoperoxide synthase 1 gene-derived protein. Proc Natl Acad Sci U S A (2004) 0.94
COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors. Gut (2000) 0.94
The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations. Hepat Mon (2014) 0.93
Aspirin and other anti-inflammatory drugs. Thorax (2000) 0.93
Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study. PLoS One (2011) 0.93
Inhibition of CD36-dependent phagocytosis by prostaglandin E2 contributes to the development of endometriosis. Am J Pathol (2009) 0.92
Hyaluronidase recruits mesenchymal-like cells to the lung and ameliorates fibrosis. Fibrogenesis Tissue Repair (2011) 0.92
Roles of nitric oxide synthase and cyclooxygenase in leg vasodilation and oxygen consumption during prolonged low-intensity exercise in untrained humans. J Appl Physiol (1985) (2010) 0.92
Neostigmine interactions with non steroidal anti-inflammatory drugs. Br J Pharmacol (2002) 0.92
Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci (2013) 0.92
Nonsteroidal anti-inflammatory drugs in the treatment of low back pain. J Pain Res (2012) 0.91
Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci (2006) 0.90
Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf (2015) 0.89
The roles of injury and nonsteroidal anti-inflammatory drugs in the development and outcomes of severe group A streptococcal soft tissue infections. Curr Opin Infect Dis (2015) 0.89
Dual, but not selective, COX-1 and COX-2 inhibitors, attenuate acetic acid-evoked bladder irritation in the anaesthetised female cat. Br J Pharmacol (2006) 0.89
Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol (2002) 0.89
Cyclo-oxygenase type 2-dependent prostaglandin E2 secretion is involved in retrovirus-induced T-cell dysfunction in mice. Biochem J (2004) 0.89
Complement C5b-9-mediated arachidonic acid metabolism in glomerular epithelial cells : role of cyclooxygenase-1 and -2. Am J Pathol (2000) 0.88
n3 and n6 polyunsaturated fatty acids differentially modulate prostaglandin E secretion but not markers of lipogenesis in adipocytes. Nutr Metab (Lond) (2009) 0.88
LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. PLoS One (2013) 0.88
The effects of nepafenac and amfenac on retinal angiogenesis. Brain Res Bull (2009) 0.88
Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J Pharmacol Exp Ther (2012) 0.87
Standardized ginger (Zingiber officinale) extract reduces bacterial load and suppresses acute and chronic inflammation in Mongolian gerbils infected with cagAHelicobacter pylori. Pharm Biol (2009) 0.87
Design and optimization of PLGA-based diclofenac loaded nanoparticles. PLoS One (2014) 0.87
Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. Rheumatol Int (2007) 0.87
The inhibitory effect of non-steroidal anti-inflammatory drugs (NSAIDs) on the monophenolase and diphenolase activities of mushroom tyrosinase. Int J Mol Sci (2011) 0.86
N-Acetylcysteine enhances the action of anti-inflammatory drugs as suppressors of prostaglandin production in monocytes. Mediators Inflamm (2002) 0.86
Preferential uptake of the non steroid anti-inflammatory drug diclofenac into inflamed tissues after a single oral dose in rats. BMC Pharmacol (2009) 0.86
Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats. Br J Pharmacol (2008) 0.86
Early upregulation of kinin B1 receptors in retinal microvessels of the streptozotocin-diabetic rat. Br J Pharmacol (2003) 0.86
Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors. Br J Pharmacol (2002) 0.86
NSAID therapy effects on healing of bone, tendon, and the enthesis. J Appl Physiol (1985) (2013) 0.85
Effects of ibuprofen treatment on the developing preterm baboon kidney. Am J Physiol Renal Physiol (2012) 0.85
Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol (2010) 0.85
Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. Br J Pharmacol (2006) 0.85
Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Br J Cancer (2002) 0.85
Pain management for dentists: the role of ibuprofen. Ann Stomatol (Roma) (2012) 0.85
Cyclooxygenase inhibition: between the devil and the deep blue sea. Gut (2002) 0.85
Disturbance of peristalsis in the guinea-pig isolated small intestine by indomethacin, but not cyclo-oxygenase isoform-selective inhibitors. Br J Pharmacol (2001) 0.84
Microsomal prostaglandin E synthase-1 and cyclooxygenase-2 are both required for ischaemic excitotoxicity. Br J Pharmacol (2010) 0.84
Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality. Cancers (Basel) (2012) 0.84
SERCaMP: a carboxy-terminal protein modification that enables monitoring of ER calcium homeostasis. Mol Biol Cell (2014) 0.84
Increased NF-kappaB DNA binding but not transcriptional activity during apoptosis induced by the COX-2-selective inhibitor NS-398 in colorectal carcinoma cells. Br J Cancer (2003) 0.84
COX-1 vs. COX-2 as a determinant of basal tone in the internal anal sphincter. Am J Physiol Gastrointest Liver Physiol (2008) 0.84
Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel) (2012) 0.84
Pharmacology of drugs used to treat osteoarthritis in veterinary practice. Inflammopharmacology (2003) 0.84
In vitro cytotoxic evaluation of some synthesized COX-2 inhibitor derivatives against a panel of human cancer cell lines. Res Pharm Sci (2013) 0.84
Disparate effects of non-steroidal anti-inflammatory drugs on apoptosis in guinea-pig gastric mucous cells: inhibition of basal apoptosis by diclofenac. Br J Pharmacol (2002) 0.83
Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis. Ther Clin Risk Manag (2008) 0.83
Prediction of the potency of mammalian cyclooxygenase inhibitors with ensemble proteochemometric modeling. J Cheminform (2015) 0.83
New NSAID targets and derivatives for colorectal cancer chemoprevention. Recent Results Cancer Res (2013) 0.83
Atherogenic diet causes lethal ileo-ceco-colitis in cyclooxygenase-2 deficient mice. Prostaglandins Other Lipid Mediat (2007) 0.83
Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity. Elife (2016) 0.83
The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart (2006) 0.83
Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol (2003) 0.82
Mechanisms underlying the anti-inflammatory activity and gastric safety of acemetacin. Br J Pharmacol (2007) 0.82
Pharmacological evaluation of the role of cyclooxygenase isoenzymes on the micturition reflex following experimental cystitis in rats. Br J Pharmacol (2000) 0.82
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53
Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol (1998) 7.22
COX-2 inhibitors. Lancet (1999) 5.49
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A (1993) 4.82
Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med (1998) 2.32
Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest (1996) 2.31
Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs (1990) 2.29
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature (1980) 2.24
Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol (1998) 2.02
Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology (1993) 1.90
Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol (1994) 1.82
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther (1994) 1.79
Meloxicam. Drugs (1996) 1.75
Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet (1997) 1.67
Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J (1999) 1.64
Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol (1997) 1.41
Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs (1994) 1.40
Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol (1997) 1.38
A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res (1996) 1.27
Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin Pharmacokinet (1997) 1.26
Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet (1994) 1.15
Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet (1995) 1.06
Clinical pharmacokinetics of naproxen. Clin Pharmacokinet (1997) 1.05
Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res (1996) 1.00
Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy. FASEB J (1999) 0.99
Etodolac clinical pharmacokinetics. Clin Pharmacokinet (1994) 0.99
The epidemiology of NSAID gastropathy: the ARAMIS experience. J Clin Rheumatol (1998) 0.93
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53
Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature (1969) 13.60
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Prostaglandins: their disappearance from and release into the circulation. Nature (1967) 8.66
The release and fate of vaso-active hormones in the circulation. Br J Pharmacol (1969) 7.90
Prostaglandins released by the spleen. Nature (1968) 7.61
Electronic communication with patients. Evaluation of distance medicine technology. JAMA (1997) 5.85
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A (1993) 4.82
Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 4.77
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A (1991) 4.50
Inactivation of prostaglandins by the lungs. Nature (1970) 4.47
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Preparing a medical informatics research grant proposal: general principles. Comput Biomed Res (1989) 4.39
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11
The clinical value of computerized information services. A review of 98 randomized clinical trials. Arch Fam Med (1996) 4.00
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol (1972) 3.54
Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature (1972) 3.30
Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28
Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci U S A (1994) 3.20
Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20
A new approach to anti-inflammatory drugs. Biochem Pharmacol (1979) 2.95
Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A (1988) 2.84
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature (1991) 2.82
Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67
The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci U S A (1990) 2.63
Pharmacokinetic function of the pulmonary circulation. Physiol Rev (1974) 2.52
The release of prostaglandins and rabbit aorta contracting substance (RCS) from rabbit spleen and its antagonism by anti-inflammatory drugs. Br J Pharmacol (1972) 2.52
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51
Prostaglandins, oxygen tension and smooth muscle tone. Br J Pharmacol (1972) 2.51
Reactive oxygen species in acute lung injury. Eur Respir J (1998) 2.50
Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther (1973) 2.48
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmacol Chemother (1967) 2.44
Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea-pig lungs. Br J Pharmacol (1973) 2.42
Phospholipase A2 activity of guinea-pig isolated perfused lungs: stimulation, and inhibition by anti-inflammatory steroids. Br J Pharmacol (1978) 2.41
The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A (1995) 2.36
Isoforms of nitric oxide synthase. Characterization and purification from different cell types. Biochem Pharmacol (1991) 2.34
The contribution of prostaglandin production to contractions of the isolated uterus of the rat. Br J Pharmacol (1973) 2.33
Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol (1993) 2.32
Effect of physician reminders on preventive care: meta-analysis of randomized clinical trials. Proc Annu Symp Comput Appl Med Care (1994) 2.30
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Conversion of angiotensin I to angiotensin II. Nature (1967) 2.26
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature (1980) 2.24
Release of prostaglandin E-1 from the rat stomach. Nature (1967) 2.13
Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci U S A (1989) 2.08
Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol (1973) 2.07
The effects of prostagladin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and certain other smooth muscle preparations [proceedings]. Br J Pharmacol (1976) 2.06
Cardiovascular outcomes among sildenafil users: results of the International Men's Health Study. Int J Clin Pract (2008) 2.03
The release of catechol amines from the adrenal medulla by histamine. Br J Pharmacol Chemother (1965) 2.00
Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res (2008) 2.00
Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci U S A (1993) 1.96
Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur J Pharmacol (1989) 1.95
Fate of angiotensin I in the circulation. Nature (1968) 1.94
Endothelial cells metabolize NG-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine. Biochem Biophys Res Commun (1990) 1.94
Metabolism of the angiotensins in isolated perfused tissues. Nature (1969) 1.91
In search of controlled evidence for health care quality improvement. J Med Syst (1997) 1.90
5-hydroxytryptamine in the circulation of the dog. Nature (1967) 1.88
The distribution and metabolism of arachidonic acid in rabbit platelets during aggregation and its modification by drugs. Br J Pharmacol (1977) 1.87
Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins (1978) 1.85
Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol (1978) 1.85
Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol (1994) 1.82
Proceedings: Prostaglandin generation maintains the smooth muscle tone of the rabbit isolated jejunum. Br J Pharmacol (1972) 1.80
The Medline/full-text research project. J Am Soc Inf Sci (1991) 1.80
The detection and estimation of bradykinin in the circulating blood. Br J Pharmacol Chemother (1967) 1.80
Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci U S A (1987) 1.80
Teaching human genetics in biochemistry by computer literature searching. Am J Hum Genet (1989) 1.79
Deletions of different segments of the long arm of chromosome 4. Am J Med Genet (1981) 1.72
The pathogenesis of lung injury following pulmonary resection. Eur Respir J (2000) 1.69
New thoughts about medical students as effective searchers of MEDLINE. Acad Med (1990) 1.69
The effects of alteration of blood-volume on the concentration of circulating angiotensin in anaesthetized dogs. J Physiol (1966) 1.66
Partial purification of rabbit aorta contracting substance-releasing factor and inhibition of its activity by anti-inflammatory steroids. Nature (1976) 1.65
The generation from arachidonic acid of rabbit aorta contracting substance (RCS) by a microsomal enzyme preparation which also generates prostaglandins. Br J Pharmacol (1972) 1.65
Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol (1995) 1.63
Students online: learning medical genetics. Am J Hum Genet (1993) 1.62
Effect of ethnic media on cervical cancer screening rates. Aust N Z J Public Health (1997) 1.61
Prostacyclin is a circulating hormone. Nature (1978) 1.60
Synthesis of 6-keto-PGF1alpha by ram seminal vesicle microsomes. Prostaglandins (1977) 1.57
Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins (1976) 1.56
Immune interactions between mosquitoes and their hosts. Parasite Immunol (2006) 1.53
The mode of action of aspirin and similar compounds. J Allergy Clin Immunol (1976) 1.52
Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci U S A (1997) 1.52
Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci U S A (1988) 1.51
Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol (1993) 1.51
Effects on smooth muscle preparations of unidentified vasoactiv peptides from intestine and lung. Nature (1970) 1.51
Eicosanoids in inflammation. Ann Clin Res (1984) 1.50
Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A (1991) 1.50
A retinoic acid response element is part of a pleiotropic domain in the phosphoenolpyruvate carboxykinase gene. Proc Natl Acad Sci U S A (1991) 1.48
Rapid reduction of prostaglandin 15-hydroxy dehydrogenase activity in rat tissues after treatment with protein synthesis inhibitors. Br J Pharmacol (1975) 1.48